SCI 발표논문

SCI 발표논문

← SCI 발표논문 목록

Cancers (Basel). 2022;14(6):cancers14061470.

Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis.

, , , , , , , , , , ,

제1저자 원호륜, 전언주 · 교신저자 박영주, 구본석

소속 (11)
  1. Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon 35015, Korea.
  2. Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University Sejong Hospital, Sejong 30099, Korea.
  3. Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu 42472, Korea.
  4. Department of Otorhinolaryngology-Head and Neck Surgery, Chungnam National University Hospital, Daejeon 35015, Korea.
  5. Division of Endocrinology and Metabolism, Departments of Internal Medicine, Chungnam National University Hospital, Daejeon 35015, Korea.
  6. Division of Endocrinology and Metabolism, Department of Medicine, Sungkyunkwan University School of Medicine, Seoul 16419, Korea.
  7. Department of Internal Medicine, Konyang University Hospital, Daejeon 35365, Korea.
  8. Department of Surgery, Inje University Busan Paik Hospital, Busan 47392, Korea.
  9. Department of Surgery, Ulsan University College of Medicine, Seoul 05505, Korea.
  10. Department of Internal Medicine, Eulji University College of Medicine, Daejeon 34824, Korea.
  11. Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.

Abstract

There is no clear evidence that post-operative maintenance of thyroid-stimulating hormone (TSH) in the mid to lower reference range (0.5-2 mU/L) improves prognosis in patients undergoing thyroid lobectomy for low-risk differentiated thyroid cancer (DTC). The purpose of this systematic review and meta-analysis was to compare and analyze the recurrence rate according to whether the serum TSH level was maintained below 2 mU/L in patients who underwent thyroid lobectomy for low-risk DTC. Clinical data and outcomes were collected from MEDLINE, Embase, and the Cochrane Database of Systematic Reviews. The inclusion criteria were related studies on TSH maintenance or serum TSH concentration after surgery for DTC. Seven observational studies with a total of 3974 patients were included in this study. In the patients who received TSH maintenance less than 2 mU/L, the recurrence rate during the follow-up period was 2.3%. A subgroup analysis of five studies showed that the odds ratio for recurrence in patients who received TSH maintenance was 1.45 (p-value = 0.45) compared to patients who did not receive TSH maintenance. In conclusion, the evidence for the effectiveness of post-operative TSH maintenance less than 2 mU/L in patients undergoing thyroid lobectomy for low-risk DTC is insufficient.

Keywords

differentiated thyroid cancerrecurrence ratethyroid cancerthyroid lobectomythyroid-stimulating hormone

Figures

Figure 1
Figure 1 Flow diagram showing the selection of studies for inclusion in the systematic review and meta-analysis.
Figure 2
Figure 2 Risk of bias summary using ROBINS-I tool. (Red circle: high risk, green circle: low risk).

그림 출처: PubMed Central 공개 논문 (PMC8946503)

Conflict of interest statement

None of the authors have a relevant financial relationship with a commercial interest.

그 밖의 정보
출판 형태
Journal Article, Review
저널
Cancers · ISSN 2072-6694
전자 출판
2022-03-13
연구비
Korea Health Industry Development Institute HI19C0481 · Korea Health Industry Development Institute HC19C0103 · National Research Foundation of Korea 2019R1C1C1006453
참고문헌
44편